En este documento se desarrolla un marco analítico para explorar tentativamente el concepto de eco-innovación y su implantación en las empresas mexicanas de alojamiento turístico a través de dos ...características internas básicas de dichas organizaciones: su resultado empresarial y su tamaño, medido en número de cuartos. Para ello se ha realizado un conjunto de estudios de casos de seis grupos hoteleros de capital netamente mexicano. Los hallazgos sugieren que la inclinación empresarial hacia la eco-innovación está vinculada directamente con la evolución de sus resultados empresariales y con su tamaño. La eco-innovación se percibe como una apuesta estratégica generadora de ventajas comparativas para las organizaciones empresariales mexicanas estudiadas más allá de las señales emitidas por una demanda del mercado cada vez más concienciada ecológicamente y responsable con el medio y más allá de las acciones reguladoras gubernamentales.
El objetivo de este trabajo es analizar cómo afecta el cambio tecnológico a la industria editorial española y como esta se va adaptando al nuevo entorno digital. En el trabajo se ofrece una visión ...general de cuál es la situación del sector editorial en España a través de la recopilación de datos procedentes, principalmente, de fuentes de información secundaria, tanto pública como privada, desde el año 1996 hasta el 2017, lo que ha supuesto revisar una gran cantidad de documentos de diferentes procedencias y agrupar los datos obtenidos, generando una serie temporal que permite vislumbrar cuál es el estado y la evolución de la digitalización en la industria editorial española en estos casi veinte años. En este documento se hace referencia a los nuevos modelos de negocio que surgen como consecuencia de la digitalización, para finalmente cerrar con unas conclusiones y limitaciones del trabajo. Este trabajo no deja sino de ser una muestra del pasado, presente y futuro de la industria del libro en España, pero supone el primer paso para continuar investigando otros aspectos de una manera más profunda.
Eco-innovation is shown as one of the great challenges of the tourism industry given the growing connection between environmental quality and its good performance. Although the tourism literature has ...considered the topic of business sustainability in broader terms, the notion of eco-innovations represents a new field of research with studies that still investigate in depth the adoption of eco-innovations among tourism companies. This work addresses the conceptual evolution of eco-innovation to subsequently develop an analytical framework that tentatively explores this concept and its implementation in Mexican tourist accommodation companies through two basic internal characteristics of these organizations: their business performances and their respective sizes, measured in number of rooms. The methodology used has been the case method, making a set of case studies related to six hotel groups of purely Mexican capital through documentary evidence and structured interviews. The conclusions derived from the findings suggest, firstly, that eco-innovation is directly linked to the evolution of business results and the size of organizations and, secondly, that eco-innovation is perceived as a strategic bet generating comparative advantages for Mexican companies studied, independently of the signals issued by an ecologically aware demand and beyond the governmental regulatory actions.
Schistosomiasis is highly endemic in sub-Saharan Africa and frequently imported to Europe. Male urogenital manifestations are often neglected. We aimed to ascertain the prevalence of genitourinary ...clinical signs and symptoms among long-term African migrants in a non-endemic European country using a serology test.
We carried out a prospective, community-based cross-sectional study of adult male migrants from sub-Saharan Africa living in Spain. Schistosoma serology tests and microscopic urine examinations were carried out, and clinical data were obtained from an electronic medical record search and a structured questionnaire.
We included 388 adult males, mean age 43.5 years Standard Deviation (SD) = 12.0, range: 18-76. The median time since migration to the European Union was 17 Interquartile range (IQR): 11-21 years. The most frequent country of origin was Senegal (N = 179, 46.1%). Of the 338, 147 (37.6%) tested positive for Schistosoma. Parasite eggs were present in the urine of only 1.3%. Nine genitourinary clinical items were significantly associated with positive Schistosoma serology results: pelvic pain (45.2%; OR = 1.57, 95% CI: 1.0-2.4), pain on ejaculation (14.5%; OR = 1.85, 95% CI: 1.0-3.5), dyspareunia (12.4%; OR = 2.45, 95% CI: 1.2-5.2), erectile dysfunction (9.5%; OR = 3.10, 95% CI: 1.3-7.6), self-reported episodes of infertility (32.1%; OR = 1.69, 95% CI: 1.0-2.8), haematuria (55.2%; OR = 2.37, 95% CI: 1.5-3.6), dysuria (52.1%; OR = 2.01, 95% CI: 1.3-3.1), undiagnosed syndromic STIs (5.4%), and orchitis (20.7%; OR = 1.81, 95% CI: 1.0-3.1). Clinical signs tended to cluster.
Urogenital clinical signs and symptoms are prevalent among male African long-term migrants with a positive Schistosoma serology results. Genital involvement can be frequent even among those with long periods of non-residence in their sub-Saharan African countries of origin. Further research is needed to develop diagnostic tools and validate therapeutic approaches to chronic schistosomiasis.
Abstract 1766
The MPD are characterized by clonal neoplastic proliferation of one or more of the myeloid lineage in the bone marrow. The BCR/ABL fusion gene is a key genetic marker for CML an the ...mutation JAK2 V617F is present by over 95% of patients with PV and more than 50% of patients with ET and IMF. Both JAK2 V617F and BCR/ABL result in perturbation of tyrosine kinases and their downstream signaling pathway. The coexistence of BCR/ABL fusion gene and JAK2 V617F mutation have been described in some cases. In the differential diagnosis of MPD vs CML we performed both determinations BCR/ABL fusion gene and JAK2 V617F mutation and observed high frequency of the coexistence.
We performed 350 JAK2V617F and 1500 BCR-ABL PCR assays in LAOH, between January 2011 and July 2012, for the patients with suspected MPD vs CML that were sent from diferents hospitals. This cases without definitive diagnosis were maked both test and the cohort was of 142 patients. Peripheral blood or bone marrow samples were included of 56 cases with CML, 48 cases of isolated thrombocytosis, 34 cases in which total blood count disclosed elevation of ≥2 myeloid cell types and 4 cases with PV diagnosis. RNA and DNA were extracted using Trizol® reagent and Quiagen® commercial kit, the RT-PCR from b3a2/b2a2 BCR-ABL transcript was performed according to protocols standarized. For JAK2 V617F we using the allele-specific PCR method and the restiction enzyme method with BsaXI enzyme wich restriction site is present in exon 14 of JAK2. To validate the specificity of our result we sequenced the PCR products in 10 cases and two normal controls.
Of the 142 patients evaluated for both JAK2 V617F and BCR-ABL fusion gene, 18 patients were positive for both (12.7%). Ten with CML de novo, seven cases with ET, and one case in follow-up with imatinib. The average age of these JAK2 V617F mutation and BCR-ABL positive patients (n=18) was 63.5 (ranging from 45–82) and in patients JAK2 V617F mutation and BCR-ABL negative (n=124) were 58 years old (rank 18–85). The patient with CML in therapy with imatinib by one year, was present increase WBC; and his molecular analysis for JAK2 V617F was positive and also BCR/ABL+. The patient′s treatment regimen was modified, with initiation of hydroxyurea and imatinib; the patient achieved complete hematological response.
The others cases reports in the literature are most often a JAK2 V617F+ MPN developed in the setting of a previously diagnosed CML undergoing treatment with a tyrosine kinase inhibitor, or alternately, CML developed months to years after patients had been diagnosed with a JAK2 V617F+ MPN. In this report the most of our cases the BCR-ABL and JAK2 V617F positive cells were detected before the treatment. This studies have suggested two possibilities to account for expression of BCR-ABL and JAK2 V617F anomalies concomitant in a single patient. The first is that there are two clones each having BCR-ABL and JAK2 V617F mutation and another possibility is a single clone concurrently possesses both BCR-ABL and JAK2 V617F. It remains to be seen whether or not this patients would benefit from combined treatment with tyrosine kinase inhibitor and interferon or hydroxyurea. The clinical following up of this patients help us to response this questions. We have the highest frequency of concurrent JAK2 V617F mutation and BCR-ABL fusion gene reported, but is neccessary determined the true incidence in a greater number of patients with CML and MPD.
No relevant conflicts of interest to declare.
PDF
